Note 20 - Subsequent Events

9 Months Ended

Feb. 29, 2016

20.	SUBSEQUENT EVENTS

On March 4, 2016, the Company exercised its warrant and acquired 100% of the common stock of Sirona Genomics, Inc. (“Sirona”). The cash paid for the Sirona business was $14.4 million. Immucor has been in a collaborative arrangement with Sirona since October 2014 for the development and commercialization of a next generation sequencing HLA typing product for transplant diagnostics.

Sirona will be included in the Company’s consolidated financial statements beginning in the fourth quarter of fiscal year 2016.

On April 5, 2016, the Company announced a plan to consolidate its LIFECODES facilities to simplify the operations, improve the processes, and reduce expenses of its Transplant business. The plan includes closing the Company’s Stamford, CT facility and moving most of the activity to the Company’s Waukesha, WI site with a target completion date of April 30, 2017.